Bardia A, Vahdat LT, Diamond J, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results. SABCS 2017, GS1-07.
Effect van HPV-vaccinatie in Engeland over sociaaleconomische groepen
sep 2024 | Gynaecologische oncologie, Vaccinatie, Virale infecties